## WHAT IS CLAIMED IS:

- 1. A composition comprising a glycoprotein having an immunoglobulin CH2 domain said CH2 domain having at least one N-linked oligosaccharide wherein substantially all of the oligosaccharide is a G2 oligosaccharide.
- 2. The composition of claim 1 wherein the glycoprotein is an antibody.
- 3. The composition of claim 2 wherein the antibody is a monoclonal antibody.
- 4. The composition of claim 3 wherein the antibody is an IgG.
- 5. The composition of claim 4 wherein the IgG is human  $\ensuremath{\text{IgG}_1}$ .
- 6. The composition of claim 5 wherein the monoclonal antibody is selected from the group consisting of an anti-CD20 specific monoclonal antibody, an anti-HER2 specific monoclonal antibody, and anti-VEGF specific monoclonal antibody, and an anti-IgE specific monoclonal antibody.
- 7. The composition of claim 1 wherein the glycoprotein is an immunoadhesin.
- 8. The composition of claim 7 wherein the immunoadhesin is a tumor necrosis factor-immunoglobulin G1 chimera.
  - 9. The composition of claim 1 wherein the glycoprotein is

an antibody-immunoadhesin chimera.

10. A method of producing the composition of claim 1 comprising the steps of

reacting in an aqueous buffered solution at a temperature of about  $25-40^{\circ}$  C;

- a) a metal salt at a concentration of about 5 mM to about 25  $\,\mathrm{mM}$ ;
- b) an activated galactose at a concentration of about 5 mM to about 50 mM;
- c) a galactosyltransferase at a concentration of about 1 mUnit/ml to about 100 mUnit/ml;
  - d) a substrate glycoprotein; and recovering the glycoprotein.
- 11. The method of claim 10 wherein the metal salt is selected from the group consisting of Mn2++, Ca2++, and Ba2++.
- 12. The method of claim 11 wherein the activated galactose is uridine diphosphate-galactose (UDP-galactose).
- 13. The method of claim 12 wherein the galactosyl transferase is a mammalian  $\beta 1\text{--}4$ , galactosyl transferase.
- 14. The method of claim 13 wherein the reaction temperature is about 37° C, the metal salt is Mn2++ at a concentration of about 5 mM, the UDP-galactose concentration is about 5 mM and the  $\beta$  1-4 galactosyl transferase concentration is about 1 mUnit/ml.
- 15. The method of claim 14 wherein the glycoprotein is an antibody.

- 16. The method of claim 15 wherein the antibody is an IgG.
- 17. The method of claim 16 wherein the IgG is human IgG1.
- 18. The method of claim 17 wherein the monoclonal antibody is selected from the group consisting of an anti-CD20 specific monoclonal antibody, an anti-HER2 specific monoclonal antibody, and anti-VEGF specific monoclonal antibody, and an anti-IgE specific monoclonal antibody.
- 19. The method of claim 13 wherein the glycoprotein is an immunoadhesin.
- 20. The method of claim 19 wherein the immunoadhesin is a bispecific immunoadhesin.
- 21. The method of claim 13 wherein the glycoprotein is an antibody-immunoadhesin chimera.
- 22. A method for the treatment of a disease state comprising administering to a mammal in need thereof a therapeutically effective dose of the composition of claim 1.
- 23. A method for the treatment of a disease state comprising administering to a mammal in need thereof a therapeutically effective dose of the composition of claim 6.
- 24. The method of claim 22 wherein the disease state is selected from the group consisting of inflammatory disorder, cancer, neurofibromatosis, peripheral neuropathologies, and cardiac hypertrophy.

- 25. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.
- 26. A pharmaceutical composition comprising the composition of claim 6 and a pharmaceutically acceptable carrier.
- 27. A pharmaceutical composition comprising the composition of claim 7 and a pharmaceutically acceptable carrier.
  - 28. An article of manufacture, comprising:
  - a container;
  - a label on said container; and the composition of claim 1 contained within said container;
- 29. The article of claim 28 wherein the label on the container indicates that the composition can be used for the treatment of cancer.